Cargando…
Adapting Drug Approval Pathways for Bacteriophage-Based Therapeutics
The global rise of multi-drug resistant bacteria has resulted in the notion that an “antibiotic apocalypse” is fast approaching. This has led to a number of well publicized calls for global funding initiatives to develop new antibacterial agents. The long clinical history of phage therapy in Eastern...
Autores principales: | Cooper, Callum J., Khan Mirzaei, Mohammadali, Nilsson, Anders S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971087/ https://www.ncbi.nlm.nih.gov/pubmed/27536293 http://dx.doi.org/10.3389/fmicb.2016.01209 |
Ejemplares similares
-
Morphologically Distinct Escherichia coli Bacteriophages Differ in Their Efficacy and Ability to Stimulate Cytokine Release In Vitro
por: Khan Mirzaei, Mohammadali, et al.
Publicado: (2016) -
Corrigendum: Morphologically Distinct Escherichia coli Bacteriophages Differ in Their Efficacy and Ability to Stimulate Cytokine Release In Vitro
por: Khan Mirzaei, Mohammadali, et al.
Publicado: (2017) -
Response: Commentary: Morphologically Distinct Escherichia coli Bacteriophages Differ in Their Efficacy and Ability to Stimulate Cytokine Release In Vitro
por: Khan Mirzaei, Mohammadali, et al.
Publicado: (2016) -
Bacteriophage Procurement for Therapeutic Purposes
por: Weber-Dąbrowska, Beata, et al.
Publicado: (2016) -
Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection
por: Benedict, Ashwini, et al.
Publicado: (2015)